PXMBF
Price
$3.50
Change
-$0.00 (-0.00%)
Updated
May 16 closing price
REMI
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Sep 20 closing price
40 days until earnings call
Ad is loading...

PXMBF vs REMI

Header iconPXMBF vs REMI Comparison
Open Charts PXMBF vs REMIBanner chart's image
PAXMAN AB
Price$3.50
Change-$0.00 (-0.00%)
Volume$600
CapitalizationN/A
Remedent
Price$0.05
Change-$0.00 (-0.00%)
Volume$28K
CapitalizationN/A
View a ticker or compare two or three
PXMBF vs REMI Comparison Chart
Loading...
VS
PXMBF vs. REMI commentary
Oct 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PXMBF is a Hold and REMI is a Hold.

COMPARISON
Comparison
Oct 18, 2024
Stock price -- (PXMBF: $3.50 vs. REMI: $0.05)
Brand notoriety: PXMBF and REMI are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: PXMBF: 100% vs. REMI: 113%
Market capitalization -- PXMBF: $56.48M vs. REMI: $3.4M
PXMBF [@Medical Specialties] is valued at $56.48M. REMI’s [@Medical Specialties] market capitalization is $3.4M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PXMBF’s FA Score shows that 0 FA rating(s) are green whileREMI’s FA Score has 0 green FA rating(s).

  • PXMBF’s FA Score: 0 green, 5 red.
  • REMI’s FA Score: 0 green, 5 red.
According to our system of comparison, PXMBF is a better buy in the long-term than REMI.

Price Growth

PXMBF (@Medical Specialties) experienced а 0.00% price change this week, while REMI (@Medical Specialties) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.01%. For the same industry, the average monthly price growth was +3.93%, and the average quarterly price growth was -2.96%.

Reported Earning Dates

REMI is expected to report earnings on Nov 27, 2024.

Industries' Descriptions

@Medical Specialties (-2.01% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

FUNDAMENTALS
Fundamentals
PXMBF($56.5M) has a higher market cap than REMI($3.4M). PXMBF YTD gains are higher at: 25.000 vs. REMI (-48.454). PXMBF has higher annual earnings (EBITDA): 21.8M vs. REMI (-192.98K). PXMBF has more cash in the bank: 29.1M vs. REMI (83.3K). REMI has less debt than PXMBF: REMI (5.46K) vs PXMBF (16.3M). PXMBF has higher revenues than REMI: PXMBF (160M) vs REMI (1.13M).
PXMBFREMIPXMBF / REMI
Capitalization56.5M3.4M1,662%
EBITDA21.8M-192.98K-11,297%
Gain YTD25.000-48.454-52%
P/E RatioN/AN/A-
Revenue160M1.13M14,172%
Total Cash29.1M83.3K34,934%
Total Debt16.3M5.46K298,808%
FUNDAMENTALS RATINGS
REMI: Fundamental Ratings
REMI
OUTLOOK RATING
1..100
29
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
92
PRICE GROWTH RATING
1..100
83
P/E GROWTH RATING
1..100
59
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL232.150.37
+0.16%
Apple
SPY582.350.05
+0.01%
SPDR® S&P 500® ETF Trust
TSLA220.89-0.44
-0.20%
Tesla
BTC.X67399.836000-212.882810
-0.31%
Bitcoin cryptocurrency
GME21.41-0.25
-1.15%
GameStop Corp

PXMBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, PXMBF has been loosely correlated with IDTA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if PXMBF jumps, then IDTA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PXMBF
1D Price
Change %
PXMBF100%
N/A
IDTA - PXMBF
53%
Loosely correlated
N/A
ANSLF - PXMBF
37%
Loosely correlated
N/A
IOBCF - PXMBF
30%
Poorly correlated
+8.39%
BLOZF - PXMBF
23%
Poorly correlated
+0.94%
BIAF - PXMBF
21%
Poorly correlated
-2.29%
More

REMI and

Correlation & Price change

A.I.dvisor tells us that REMI and AHICF have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that REMI and AHICF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REMI
1D Price
Change %
REMI100%
N/A
AHICF - REMI
23%
Poorly correlated
N/A
RDGL - REMI
3%
Poorly correlated
-5.03%
SAFLF - REMI
2%
Poorly correlated
N/A
RSCF - REMI
1%
Poorly correlated
+2.89%
PXMBF - REMI
0%
Poorly correlated
N/A
More